"Linking clinical tumour response to preclinical tumour models"

Workshop

 

15. Linking clinical tumour response to preclinical tumour models. Drug Discovery Innovation Programme (World BI), Leonardo Hotel Frankfurt City - South, Frankfurt (11/2018) PDF

​

Objectives

• Review the pain points in drug R&D

• Understand PK/PD rationales that are relevant to different types of biomarker data

• Evaluate preclinical tumour models and forecast clinical efficacy

• Raise awareness of The Open Project (TOP)

​

Lecture 1. The reason why

• Data irreproducibility crisis

• Cancer drug development attrition 

 

Lecture 2. Translational oncology modelling basics: Evaluate preclinical tumour models and forecast clinical efficacy

• Pfizer 3 pillars and AstraZeneca 5Rs

• Translational oncology modelling

Case study: Qualify A2780 xenograft as a suitable ovarian carcinoma model using PK/PD modelling

Case study: Predict clinical failure with modelling of preclinical PK/PD and clinical PK

Case study: Evaluate PC-9 xenograft as an efficacy model for EGFR by modelling preclinical PK/PD and clinical PK of afatinib

Case study: Evaluate Mia PaCa2 xenograft as an efficacy model for gemcitabine using preclinical and clinical data

​

Lecture 3. The Open Project

• Translational oncology modelling

• Openness, transparency, meritocracy